Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Active

18 and over

Other

5762
GSK-103421, NCT00577629

Trial Description

Summary

The purpose of this study is to determine whether using high-dose chemotherapy, monoclonal antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients with high-risk NHL.

Eligibility Criteria

Inclusion Criteria:

Untreated, biopsy proven B-cell non-Hodgkin's lymphoma

Age >/= 18 years

No other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for one year. The patient cannot have been exposed to chemotherapy to treat any of these diseases for at least 3 years prior to study entry.

Meet staging studies and laboratory tests prior to induction, consolidation and radioimmunotherapy.

Trial Contact Information

Trial Lead Organizations/Sponsors

Duke Comprehensive Cancer Center

GlaxoSmithkline

David A. Rizzieri

Principal Investigator

Emily Dill, RN		Ph: 919- 684-4723
		Email: edmon009@mc.duke.edu

Patty Davis, RN		Ph: 919-668-1026
		Email: davis043@mc.duke.edu

Trial Sites

U.S.A.

North Carolina

Durham

Duke Comprehensive Cancer Center

David Rizzieri, MD Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00577629
Information obtained from ClinicalTrials.gov on August 15, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.